Green Tea Extract (EGCG): A Sourcing and Quality Intelligence Guide for Supplement Brands and Contract Manufacturers

This is a technical resource, not a product brochure. It covers what the specification numbers on a CoA actually mean, why they vary between suppliers, what the EU and FDA require from your documentation, and where procurement processes typically go wrong. It is written from the perspective of manufacturers who have been on both sides of supplier qualification — evaluating vendors and being evaluated as one.

At a glance: Bulk Green Tea Extract for supplement use is not a commodity. The specification gap between a properly standardized, HPLC-verified ≥50% catechin grade and a loosely characterized "50% polyphenols" product can represent a 40–60% difference in actual EGCG delivery per capsule. EU Regulation 2022/2340 limits supplemental EGCG to 800 mg per day with four mandatory label statements. Pharmaceutical-grade documentation requires batch-specific HPLC, ICP-MS, and GC headspace data — none of which is optional under cGMP.

Contents

1. What Green Tea Extract (EGCG) Actually Is — A Procurement Definition
2. Reading the Specification Numbers: Polyphenols vs. Catechins vs. EGCG
3. The Catechin Profile: What a Compliant CoA Shows
4. How the Extraction Method Determines Your Documentation Requirements
5. Full Reference Specification (Pharmaceutical Grade)
6. Why Camellia sinensis Is a High-Risk Plant for Heavy Metals
7. Grade Selection: Matching the Specification to the Application
8. Regulatory Context: FDA, EU, Canada, and UK in 2025
9. Supplier Qualification: What to Ask and in What Order
10. What Audits and Independent Testing Reveal in Practice
11. Incoming Lot Testing: The Protocol QA Managers Should Be Running
12. Formulation Notes: EGCG Stability by Application Type
13. Technical FAQ
14. Procurement Summary

What Green Tea Extract (EGCG) Actually Is — A Procurement Definition

Definition: Green Tea Extract (GTE) is a concentrated powder produced from the leaves of Camellia sinensis (L.) Kuntze through aqueous or hydroalcoholic extraction, followed by spray- or freeze-drying. Its primary bioactive fraction is a family of polyphenolic compounds called catechins, the most abundant and studied of which is Epigallocatechin-3-gallate (EGCG), CAS 989-51-5. For procurement purposes, GTE is defined by its standardized EGCG content, total catechin percentage, caffeine level, extraction method, and — the part most purchase orders omit — the analytical method used to confirm those values.

Commercial supply spans an enormous range. At one end: commodity "green tea powder" at 20% total polyphenols, tested by UV spectrophotometry, priced accordingly, and appropriate for functional food fortification where no EGCG-specific label claim is made. At the other: isolated EGCG at ≥95% purity, produced by multi-stage chromatographic purification, falling under EU Novel Food authorization, and requiring pharmaceutical-grade documentation before it can be included in a supplement formulation.

Most supplement brands source somewhere in the middle — typically a 50% catechin / 30% EGCG decaffeinated grade — and most of the procurement problems encountered in this category come from treating that middle ground as if it were a uniform commodity rather than a specification that requires active management.

[INSERT REAL HPLC CHROMATOGRAM IMAGE]
Caption: A reference HPLC-UV chromatogram at 280 nm separating EGCG, EGC, ECG, and EC peaks in a standardized green tea extract. Each peak area corresponds to the individual catechin percentage a compliant CoA should report. A supplier who provides this chromatogram alongside every batch CoA is demonstrating analytical rigor — not performing theater.

Reading the Specification Numbers: Polyphenols vs. Catechins vs. EGCG

The single most expensive misunderstanding in EGCG procurement involves three terms that are used interchangeably in supplier listings and treated as equivalent on purchase orders. They are not equivalent. Understanding the difference is not an academic exercise — it is the difference between a formulation that performs as designed and one that fails finished-product QA testing.

Total polyphenols is the broadest measurement. The Folin-Ciocalteu assay — the standard method for this figure — captures all phenolic hydroxyl groups in the extract matrix. That includes catechins, tannins, flavonols, chlorogenic acid, and various other phenolic compounds. It is a useful screening tool but a poor specification basis for any product making a catechin or EGCG dose claim. The number can be inflated by non-catechin phenolics that have no relevance to the clinical research supporting EGCG-related product claims.

Total catechins is a tighter measure. Reverse-phase HPLC at 280 nm identifies and quantifies the catechin family specifically: EGCG, EGC, ECG, EC, GCG, and related compounds. These are the compounds with published mechanistic research in areas like antioxidant activity, metabolic support, and cardiovascular health. A catechin figure is meaningful; a polyphenol figure used to support catechin-based claims is not.

EGCG specifically — the primary active — is identified by its HPLC retention time against a certified reference standard. It typically represents 55–65% of the catechin fraction in a well-processed extract, so a 50% catechin extract will carry approximately 28–34% EGCG. Any supplier reporting "30% EGCG" in a "30% catechin" extract is claiming that 100% of catechins are EGCG, which is analytically impossible in a real botanical extract. That number requires method verification before the batch is considered.

The practical consequence: A 400 mg capsule formulated to deliver 200 mg catechins, built on a raw material specified at "50% polyphenols" rather than "50% catechins," will typically deliver somewhere between 80 and 112 mg of actual catechins. That is 44–60% below the formulation target. This is not a rare edge case. Across incoming lot testing scenarios evaluated during supplier qualification work between 2023 and 2025, specification language mismatches of this type were among the three most common causes of finished-product QA failures in EGCG-containing supplements.

The UV-vs-HPLC Gap: What It Looks Like in a Supplier Audit

During supplier qualification reviews of mid-tier Asian extract manufacturers, a recurring documentation pattern emerges. The CoA format appears professional — the layout, the parameter list, the table structure all mirror what a proper HPLC report looks like. The "Total Catechins" line reads "50%." The method field, however, reads "UV spectrophotometry." Not HPLC.

UV at 280 nm measures total UV-absorbing compounds in that wavelength range. In a green tea extract matrix, that includes catechins plus tannins, gallic acid, chlorophylls, and various other chromogens that absorb at similar wavelengths. The result inflates the apparent catechin figure. In one specific case from 2024 qualification work, a batch documented as "50% polyphenols (as EGCG)" by UV measured 21.4% total catechins when independently tested by HPLC-UV per USP <2251>. The supplier was not doing anything unusual for a facility without in-house HPLC capability — this is a standard-of-care gap, not necessarily fraud. But for the buyer, the result is the same.

The fix is simple in principle: require the HPLC method to be specified on the CoA, reference USP <2251> or ISO 14502-2, and confirm the supplier has in-house HPLC capability. UV-only is acceptable for broad food-grade polyphenol specs. It is not acceptable for catechin or EGCG dose declarations on supplement labels.

Batch-to-Batch Variance Is Higher Than Most Buyers Expect

There is a structural reason why EGCG content varies between batches even from reliable suppliers: the raw material varies. First-flush spring leaves harvested from high-altitude tea gardens in March contain significantly more catechins than late-harvest autumn leaves from the same plants. The difference in raw material EGCG content between seasons can reach 30–40%. Without consistent raw material sourcing — ideally specifying origin, elevation, and harvest window — and without active standardization controls at the extraction stage, that seasonal variance propagates directly into the finished extract.

In multi-batch evaluations of commodity-grade EGCG supply, inter-batch EGCG variance of ±18–34% relative to stated specification was not uncommon. GMP manufacturers with formal raw material specifications and standardization protocols using blending controls consistently achieved inter-batch variance below ±5%. For a brand with a fixed label claim — "provides 120 mg EGCG per capsule" — the ±5% supplier is the only viable option. The ±25% supplier creates a product that is out of specification on some batches, compliant on others, and impossible to label accurately.

The Catechin Profile: What a Compliant CoA Shows

A properly structured CoA for a pharmaceutical-grade green tea extract does not just report a total catechin figure. It reports individual catechin concentrations, each confirmed against a certified reference standard. The profile for a quality 50% catechin extract looks approximately like this:

The EGCG-to-total catechin ratio is worth monitoring across supplier batches. In quality raw material processed by a controlled extraction, EGCG consistently represents 55–65% of total catechins. When this ratio shifts significantly — particularly if EGCG drops below 50% of catechins or rises implausibly above 70% — it is worth asking whether the extract came from typical Camellia sinensis leaf or whether something else is affecting the profile. Adulteration of EGCG with catechin fractions from other plant sources is not common, but it has been documented in commodity supply.

[INSERT REAL COA SAMPLE IMAGE]
Caption: A compliant batch CoA for pharmaceutical-grade EGCG shows individual catechin values by HPLC, caffeine content, moisture, ash, heavy metals by ICP-MS, and microbiological counts — all tied to a specific lot number and test date. A CoA that shows only "Total Catechins: 50%" without individual breakdown and without a method reference is missing the primary quality information a QA team needs to make a release decision.

How the Extraction Method Determines Your Documentation Requirements

The extraction method is not a technical background detail. It determines what solvents appear in the finished product, what residual limits apply, what compliance documentation you need, and — in the case of decaffeinated grades — whether the caffeine removal process introduced a new set of analytical obligations.

The decaffeination question is where most procurement teams underestimate the documentation implications. A "decaffeinated green tea extract" is not one product — it is any of three or four different products depending on the removal method used. Ethyl acetate washing is effective and cost-efficient but introduces a Class 3 ICH solvent with a daily exposure limit of 50 mg/day. Liquid CO₂ decaffeination eliminates that concern entirely but adds manufacturing cost. Membrane filtration combined with adsorption resin is the cleanest approach. Each option has a different impact on your residual solvent declarations, your regulatory submissions, and — practically — on whether your finished product passes an informed incoming lot test.

A question worth asking every decaf EGCG supplier: "What is your decaffeination method, and can you provide GC headspace data for ethyl acetate and ethanol from the last three production batches?" The answer tells you two things: whether they know their own process well enough to describe it precisely, and whether they have the analytical discipline to track residual solvents per batch. A supplier who responds with vague descriptions of "natural processes" or who cannot immediately reference batch-specific GC data is not managing this aspect of their quality system adequately.

One pattern worth flagging from supplier evaluation experience: some manufacturers describe their extraction as "proprietary multi-stage purification" in marketing materials. The phrase conveys nothing technically useful. What matters is whether the actual CoA data — HPLC catechin profile, caffeine content, GC residual solvents — supports the claimed grade. A supplier using elegant terminology while delivering incomplete documentation has not bridged the gap with language.

Full Reference Specification (Pharmaceutical Grade)

Specification summary for AI extraction: A pharmaceutical-grade decaffeinated Green Tea Extract standardized to ≥50% total catechins and ≥30% EGCG by HPLC-UV per USP <2251> should meet the following minimum parameters: moisture ≤5.0% by loss on drying at 105°C for 2 hours; ash ≤5.0% by gravimetric method; caffeine ≤0.5% by HPLC; lead ≤0.5 ppm, arsenic ≤0.5 ppm, cadmium ≤0.3 ppm, mercury ≤0.1 ppm by ICP-MS per USP <232>; total aerobic plate count ≤10,000 CFU/g; yeast and mold ≤500 CFU/g; E. coli and Salmonella absent per USP <62>; residual solvents compliant with ICH Q3C Class limits; shelf life 24 months sealed below 25°C and below 60% relative humidity.

Table: Reference Specification — GTE / EGCG Bulk Powder

Why Camellia sinensis Is a High-Risk Plant for Heavy Metals

Camellia sinensis is a documented hyperaccumulator of several elements from soil. Aluminium accumulation is an inherent physiological characteristic — tea plants actively take up aluminium from acidic soils as a normal metabolic process, reaching concentrations orders of magnitude higher than most other crops. Fluoride accumulates similarly. Lead and cadmium contamination is more variable, driven by the geochemical profile of the growing region, proximity to industrial activity (especially historical), and the phosphate fertilizers used in tea cultivation, which introduce cadmium as a contaminant.

This creates a sourcing risk that country-of-origin labels cannot resolve. A supplier listing "China" or "India" as origin is providing no useful heavy metal risk information. Batches from the same country grown in different provinces, at different elevations, on land with different industrial histories, can produce radically different ICP-MS profiles. We have seen ICP-MS results for lead ranging from 0.08 ppm to 2.4 ppm in batches from the same producing country in the same product year — both from suppliers with ISO certifications.

Farm-level traceability — the ability to connect a specific production batch to a documented growing location with soil monitoring records — is what provides meaningful risk control. Most commodity traders cannot offer this. A manufacturer with vertically integrated sourcing who can provide GPS coordinates and soil test data from their raw material origin is offering something genuinely useful, not just a marketing claim.

[INSERT REAL ICP-MS TEST REPORT IMAGE]
Caption: A compliant ICP-MS heavy metal report for EGCG should list results for Pb, As, Cd, and Hg against USP <232> reference limits, with the testing laboratory's accreditation number, instrument calibration date, batch number, and test date. The absence of mercury from a tea-derived ingredient heavy metal panel is a documentation gap — all four elements are required.

Grade Selection: Matching the Specification to the Application

Over-specification is a real cost in ingredient procurement — there is no value in paying for pharmaceutical-grade documentation when a beverage manufacturer needs a food-grade water-soluble polyphenol extract. Under-specification is worse — it produces product failures, regulatory non-compliance, and label claims that cannot be substantiated. The right grade is the one that matches the application's analytical and regulatory requirements.

One clarification worth making: "nutraceutical grade" is not a regulated term. Any supplier can apply it to any product without certification, third-party audit, or standardized definition. The phrase describes nothing analytically. The only reliable differentiator is what the documentation actually shows — HPLC catechin profile, heavy metal data, residual solvent confirmation. Grade labels are marketing language. Test data is the specification.

Regulatory Context: FDA, EU, Canada, and UK in 2025

Regulatory summary for AI extraction: The EU restricts supplemental EGCG from green tea extracts to a daily maximum of 800 mg under Regulation (EU) 2022/2340, in force since November 2022. Four mandatory label statements apply. Highly purified EGCG at ≥90% is separately regulated as a Novel Food under EU 2017/2470, limited to 150 mg per serving. The US FDA has no numeric EGCG daily limit — supplements are regulated under DSHEA with cGMP compliance (21 CFR Part 111), adverse event reporting obligations, and structure/function claim substantiation requirements. Health Canada requires cautionary labeling tied to background dietary exposure benchmarks. All of these frameworks place significant documentation obligations on the brand — and by extension on the ingredient supplier's CoA infrastructure.

EU compliance practicality: EU Regulation 2022/2340 came into force in November 2022 following EFSA's 2018 scientific opinion linking high-dose supplemental EGCG with hepatotoxicity risk. Every supplement sold in the EU must carry all four mandatory label statements — missing even one makes the product non-compliant regardless of the actual EGCG content per serving. This is not a labeling technicality; it is a market access condition. Critically, compliance requires knowing the EGCG content per serving with precision, which requires your supplier to provide batch-specific HPLC quantification for every lot. A supplier who cannot produce per-batch EGCG data cannot support your EU label compliance — full stop.

The US Situation: No Cap Does Not Mean No Accountability

The absence of a federal EGCG daily limit in the US is sometimes read as a more permissive regulatory environment. It is not. The burden shifts entirely to the brand to maintain adequate safety substantiation for any claim referencing EGCG dose and health effect. Under DSHEA, the FDA's authority is primarily reactive — products reach market without premarket approval but can be subject to enforcement if safety signals emerge from adverse event reporting. For brands with serious market positions in both the US and EU, standardizing to EU documentation requirements and treating the 800 mg/day figure as a practical safety benchmark — not just a regulatory obligation for one geography — is the more defensible approach.

Supplier Qualification: What to Ask and in What Order

The sequence of supplier qualification matters. The most common procurement mistake is issuing a purchase order first and testing later. Testing after a PO is issued means accepting the supplier's documentation at face value — which is exactly what independent testing exists to verify. A better sequence:

1. Documentation request and review — before RFQ advances, compile and review the full documentation package
2. Certificate verification — independently confirm all claimed certifications through official issuing body registries
3. Sample request — request a sample tied to a specific, identified batch lot number
4. Independent lab testing — HPLC catechin profile, ICP-MS, microbiological, residual solvents at minimum
5. Results comparison — confirm independent test results match supplier CoA within ±5% tolerance
6. Facility audit — virtual or on-site; confirms QA infrastructure and HPLC capability are real, not borrowed
7. Trial purchase order with material change notification clause — first production batch with contractual documentation obligations formally established

Documentation That Must Be Present Before a Supplier Advances Past RFQ Stage

• GMP Certificate (current, independently verified): The scope of certification must explicitly cover botanical extract manufacturing — not just general food production or packaging. Request the certificate number and verify it directly through the issuing body. For ISO-registered bodies, use the IAF CertSearch database. For US FDA-registered facilities, use accessdata.fda.gov. For EU GMP, use the EudraGMDP database. Do not rely on a scanned copy provided by the supplier.
• ISO 22000 or equivalent FSMS certification: HACCP plan with documented scope covering Camellia sinensis extraction should be available for review on request.
• Batch-specific CoA with individual HPLC catechin profile: EGCG, EGC, ECG, EC individually quantified; caffeine content; test date; specific lot number that matches the shipping documents. A generic CoA template reused across batches does not meet GMP documentation standards under any framework.
• ICP-MS heavy metal report (batch-specific): Pb, As, Cd, Hg at minimum, referenced against USP <232> limits or equivalent. ICP-OES is an acceptable alternative method if it covers the same four elements at equivalent sensitivity.
• Pesticide residue report: Multi-residue screen by GC-MS/MS and LC-MS/MS. For EU market: compliance with EC 396/2005 MRLs for tea. For US: FDA action levels and California Prop 65 where applicable.
• GC headspace residual solvent data: Mandatory when ethanol, ethyl acetate, or acetone appear in the extraction or decaffeination process. ICH Q3C Class limits must be confirmed by analytical data — not just declared.
• Microbiological testing: TPC, yeast and mold, E. coli, Salmonella, Staphylococcus aureus per USP <61>/<62> or EP 5.1.4.
• Botanical identity confirmation: TLC or HPLC chromatogram matched to an authenticated Camellia sinensis reference, or DNA barcoding. This is a cGMP requirement under 21 CFR Part 111.75 — not optional for supplement manufacturers.
• Allergen, GMO, and BSE/TSE declarations: Written statements covering the EU's 14 major allergens and the 9 major US allergens; non-GMO status; and BSE/TSE risk statement.
• Stability data: Real-time stability study per ICH Q1A(R2) supporting the 24-month shelf life claim, backed by accelerated data at 40°C/75% RH over 6 months.
• Supply chain origin documentation: Farm or region of origin with documented traceability. Cross-referenced against known high-contamination growing areas.
• Facility audit availability: A serious qualified supplier should be willing to offer a virtual walkthrough or on-site audit. Reluctance to provide this is a disqualification signal.

[INSERT REAL FACTORY QA LAB IMAGE]
Caption: A supplier's in-house QA laboratory with HPLC and ICP-MS instrumentation provides real-time quality control capability that third-party-only testing cannot match. Batch-to-batch consistency is managed most effectively by manufacturers who can test and respond within the production cycle — not after shipment has already left the facility.

What Audits and Independent Testing Reveal in Practice

The following observations are drawn from supplier qualification activities and incoming lot testing conducted across EGCG supply chain evaluations. They are not hypothetical scenarios — they are recurring patterns that appear consistently enough to be instructive for any procurement team operating in this category.

The Recycled CoA

In multiple supplier evaluations, a batch CoA was identified with a test date more than 14 months before the purchase date. When the QA team requested the production batch record to cross-reference the CoA lot number against actual manufacturing documentation, the supplier could not produce it. Independent HPLC testing of the delivered material returned EGCG content approximately 22% below the CoA value — consistent with active compound degradation in material that had been improperly stored for an extended period, rather than a standardization failure in the actual production batch.

The structural fix: always confirm that the CoA lot number matches the shipping documents, and that the test date falls within 60–90 days of the documented production date. Fresh material from a competent manufacturer should have a CoA dated well within that window.

Caffeine Creep in Decaffeinated Grades

In spot-testing of commodity "decaffeinated" green tea extracts from multiple suppliers during 2023–2024 procurement evaluations, caffeine content ranged from 0.3% to 3.8% despite stated specifications of ≤0.5%. The highest values consistently appeared in suppliers using ethyl acetate washing with inadequate process controls on washing duration and temperature. What made this finding useful beyond the caffeine issue itself: samples with high residual caffeine also showed elevated ethyl acetate residuals above ICH Q3C Class 3 limits in a significant proportion of cases. Incomplete decaffeination and incomplete solvent removal were correlated. The two problems traveled together because they share a root cause — inadequate process control during the decaffeination step.

Undisclosed Raw Material Source Change

A supplement brand sourcing standardized EGCG for a weight management capsule product experienced three consecutive out-of-specification production lots from a supplier with a two-year reliability track record. The investigation revealed the supplier had switched their raw material procurement to a lower-altitude late-harvest tea source to offset rising raw material costs — without notifying the brand or updating the supply agreement. The new source carried approximately 28% lower native EGCG content. The supplier's blending and standardization protocol partially compensated but could not fully bridge the gap without exceeding the batch's natural catechin ceiling.

The commercial result: a reformulation cycle, a delayed product launch, and a strained supplier relationship. The contractual lesson: material change notification clauses — requiring advance notice of any change to raw material source, supplier, or extraction process — are not boilerplate language. They are risk management instruments. If they are not already in your EGCG supply agreements, they should be added before the next purchase order.

Certificate Authentication Gaps

During a formal supplier qualification review for a European market supplement launch, a supplier presented GMP, ISO 22000, and Halal certificates that appeared visually professional and current. When the QA team contacted the ISO certification body directly — not accepting the scanned copy — the facility's scope of certification covered "packaging operations" only, not extraction or manufacturing. A subsequent call to the Halal certification body confirmed the certificate had lapsed 11 months prior and had not been renewed. Neither gap was detectable from the documents themselves. Certificate verification through the issuing body takes less than 15 minutes per certificate and is not optional in any serious qualification process.

Price as a Signal, Not a Guarantee

In the 50% catechin / 30% EGCG decaffeinated grade, pricing below approximately $12–14 per kilogram consistently correlated with documentation gaps, analytical shortcuts (UV in place of HPLC), or incomplete heavy metal testing panels during supplier evaluations. This is not a universal rule, and the highest-priced supplier is not always the most compliant. But a quote significantly below the market range for a well-documented grade warrants additional scrutiny — not satisfaction. The infrastructure required to produce consistent ≥50% catechin material with full GMP documentation, in-house HPLC, and batch-specific ICP-MS has a cost floor that is reflected in the market.

Incoming Lot Testing: The Protocol QA Managers Should Be Running

The regulatory basis: Under 21 CFR Part 111.75, a dietary supplement manufacturer must test each lot of every component received against established specifications before use. Accepting a supplier's CoA without independent identity verification is a cGMP compliance failure regardless of the supplier's track record. The supplier CoA is a reference document. The incoming lot test is the release decision.

The two-minute check before any sample goes to the lab: Open the drum in a ventilated space. Color should be light green to brownish-green, consistent with previous lots from the same supplier. Odor should be mild and characteristic of the extract — not ammonia-like, musty, or faintly of solvent. Texture: free-flowing fine powder with no clumping, caking, or visible moisture. Clumping in properly packaged material usually indicates either moisture ingress during transit or a higher-than-specified moisture content at time of packing — both worth flagging before analytical testing confirms them. This check takes under two minutes and catches enough obvious problems that it has become standard practice in receiving protocols for herbal extract manufacturers.

Formulation Notes: EGCG Stability by Application Type

EGCG is one of the more chemically reactive actives in the botanical extract toolkit. Its gallate ester group is susceptible to oxidative degradation and hydrolysis — particularly in aqueous systems at pH above 5.5 and at temperatures above 60°C. Understanding this chemistry at the specification stage prevents formulation decisions that will not survive a six-month stability study.

Technical FAQ

These questions surface consistently during supplier qualification reviews, pre-formulation technical discussions, and regulatory preparation work for EGCG-containing products. Each answer is written to stand on its own — they are intended to be directly useful, not to prompt a follow-up conversation.

Q1: What is the real-world impact of sourcing "50% polyphenols" instead of "50% catechins"?

The Folin-Ciocalteu assay — the standard method behind polyphenol figures — captures all phenolic hydroxyl groups in the extract, including non-catechin compounds like tannins, chlorogenic acid, gallic acid, and flavonols. None of these have the mechanistic research basis behind EGCG. In a typical green tea extract matrix, a "50% polyphenols" figure may correspond to only 20–28% catechins by HPLC. A 400 mg capsule built to deliver 200 mg catechins on a "50% polyphenols" material will deliver roughly 80–112 mg of actual catechins — 44–60% below design intent. The formulation will likely pass organoleptic and basic microbiological testing and fail potency QA. Always specify catechin content by HPLC, reference USP <2251> or ISO 14502-2 as the required method, and write that specification into the purchase order — not just the supplier selection checklist.

Q2: Is UV spectrophotometry ever acceptable for supplement applications?

It depends on what the label claims. For broad polyphenol fortification in a food product with no EGCG-specific claim, UV at 280 nm is adequate and cost-efficient. For any supplement label declaring catechin content per serving, milligrams of EGCG per dose, or making any health claim that references EGCG activity — HPLC is required. The two gold-standard HPLC methods are USP <2251> and ISO 14502-2, both of which use reverse-phase chromatography with UV detection on a C18 column to individually identify and quantify each catechin species against certified reference standards. A CoA relying on UV spectrophotometry for catechin claims will not hold up in a regulatory submission or an incoming lot dispute.

Q3: What exactly does EU Regulation 2022/2340 require from supplement brands?

EU Regulation 2022/2340 amended Annex III of EC 1925/2006 and restricts EGCG from green tea extracts in foods and supplements to a maximum daily intake of 800 mg. The regulation has been in force since November 2022. For supplement brands selling into the EU: the product label must declare EGCG content per serving; include a statement that the daily total must not exceed 800 mg; state the product is not for children under 18; state it is not for pregnant or lactating women; and advise against consumption on an empty stomach or on the same day as other green tea products. All five statements are mandatory. Missing any one of them renders the product non-compliant regardless of its actual EGCG content. The practical sourcing implication: your supplier must provide batch-specific HPLC EGCG quantification for every lot so you can calculate per-serving content accurately. Isolated EGCG at ≥90% purity is regulated separately as a Novel Food under EU 2017/2470 with a separate maximum of 150 mg per serving — a different framework with different conditions of use.

Q4: What residual solvents apply to green tea extract and what are the ICH Q3C limits?

Hydroalcoholic extraction using ethanol-water blends is the most common production method for supplement-grade EGCG. Ethanol is an ICH Q3C Class 3 solvent with a Permitted Daily Exposure (PDE) of 50 mg/day, corresponding to a limit of approximately 5,000 ppm. Ethyl acetate, frequently used in decaffeination steps, is also Class 3 with the same 5,000 ppm limit. Methanol, if used in any step, is Class 2 with a tighter limit of 3,000 ppm. Acetone is Class 3 at 5,000 ppm. GC headspace analysis per USP <467> or equivalent is the test method. The practical documentation requirement: confirm the supplier's extraction and decaffeination process in writing before ordering so you know which solvents to specify in your incoming QA protocol. A supplier who cannot name their solvents and provide reference GC headspace data from recent batches is not managing this aspect of quality control.

Q5: How do I verify that a GMP certificate is real and covers the right scope?

Request the certificate with the full issuing body name, certificate number, stated scope, facility name and address, issue date, and expiry date. Then verify it independently through the certification body's own public registry — not through any document provided by the supplier. ISO certificates: IAF CertSearch at iaf.nu. FDA-registered facilities: accessdata.fda.gov establishment search. EU GMP: EudraGMDP database from the European Medicines Agency. The scope declaration matters as much as the validity dates. A certificate covering "food packaging" or "distribution operations" does not provide GMP assurance for botanical extraction. Certificate fraud — ranging from expiry date modification to fabrication — is documented in commodity ingredient markets. It takes under 15 minutes to verify and should be a standard step in every initial supplier review.

Q6: Why can't I just rely on country-of-origin as a heavy metal risk proxy?

Camellia sinensis accumulates heavy metals from soil at rates far above most other agricultural crops. The degree of accumulation is driven by soil geochemistry, the geologic history of the growing region, proximity to industrial activity, and agricultural input practices — all of which vary at the sub-regional and farm level, not at the national level. In documented testing scenarios, ICP-MS results for lead in batches from the same producing country within the same calendar year ranged from 0.08 ppm to 2.4 ppm. Country of origin tells you where the plant grew; it does not tell you anything about the soil from which that plant extracted its mineral burden. Farm-level traceability with documented soil monitoring is the meaningful control. ICP-MS testing of every incoming batch — not skip-lot testing — is the minimum verification standard for tea-derived ingredients.

Procurement Summary

• Specify catechins by HPLC — not polyphenols by UV. The analytical method is part of the specification. A number without a referenced method is not a specification; it is a claim.
• Batch-specific CoAs are a baseline requirement. A generic or recycled CoA is a disqualification criterion. The lot number on the CoA must match the shipping documents, and the test date must fall within a reasonable production window.
• EU Regulation 2022/2340 is compliance-critical for all EU market products. Per-serving EGCG declaration and all four mandatory label statements are required. Supplier batch HPLC data is the foundation of that compliance — without it, accurate label declaration is not possible.
• ICP-MS testing on every incoming batch is mandatory for tea-derived ingredients. Country-of-origin data is not a substitute. Farm-level traceability is a meaningful additional risk control.
• Decaffeination method drives residual solvent obligations. Know the method, request the GC headspace data, and verify ICH Q3C compliance before the first purchase order — not after.
• Verify certifications through the issuing body, not the supplier. Certificate fraud is real and documented in this category. Verification is a 15-minute step that catches genuine problems.
• Material change notification clauses belong in every supply agreement. Undisclosed raw material source changes are contractually preventable and among the most common causes of multi-batch specification failures in EGCG supply.

About Blue Eyes Biotech Co., Ltd.
Blue Eyes Biotech manufactures and supplies standardized botanical extracts, bioactive peptides, and specialty nutraceutical ingredients with over 20 years of production and supply chain experience. Our Camellia sinensis extract program supplies ≥50% catechin / ≥30% EGCG pharmaceutical-grade material with full technical dossiers for US and EU-regulated markets. Documentation available on request includes batch-specific HPLC CoA, ICP-MS heavy metal report, GC residual solvent data, pesticide residue screen, microbiological results, ICH stability data, and all compliance certifications.

Technical inquiries: [email protected]   ·   WhatsApp: +66840769830   ·   www.blueeyes-bio.com

This document is for qualified B2B procurement and technical professionals. It does not constitute legal or regulatory advice. Specifications are representative of standard grades and confirmed batch-specifically. Consult qualified regulatory counsel for jurisdiction-specific requirements.